Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Journal of Radiological Protection : Official Journal of the Society for Radiological Protection|October 3, 2025
Outcome summary of the scientific program of the 16th IRPA CongressRenate Czarwinski, Chunsheng Li, Simon Bouffler, et al.
Oligonucleotides|December 13, 2006
2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeuticsPaula E Burmeister, Chunhua Wang, Jason R Killough, et al.
Journal of Electrocardiology|September 14, 2010
Paramedics as decision makers on the activation of the catheterization laboratory in the presence of acute ST-elevation myocardial infarctionDwayne R Young, Marc Murinson, Charles Wilson, et al.
The Lancet. Oncology|April 13, 2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialRoger D James, Robert Glynne-Jones, Helen M Meadows, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Pageof 7